BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 15239657)

  • 1. Novel azapeptide inhibitors of hepatitis C virus serine protease.
    Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M
    J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S; Wu W; Shih NY; George Njoroge F
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency.
    Arasappan A; Njoroge FG; Chan TY; Bennett F; Bogen SL; Chen K; Gu H; Hong L; Jao E; Liu YT; Lovey RG; Parekh T; Pike RE; Pinto P; Santhanam B; Venkatraman S; Vaccaro H; Wang H; Yang X; Zhu Z; Mckittrick B; Saksena AK; Girijavallabhan V; Pichardo J; Butkiewicz N; Ingram R; Malcolm B; Prongay A; Yao N; Marten B; Madison V; Kemp S; Levy O; Lim-Wilby M; Tamura S; Ganguly AK
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4180-4. PubMed ID: 16087332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
    Landro JA; Raybuck SA; Luong YP; O'Malley ET; Harbeson SL; Morgenstern KA; Rao G; Livingston DJ
    Biochemistry; 1997 Aug; 36(31):9340-8. PubMed ID: 9235976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies.
    Cicero DO; Barbato G; Koch U; Ingallinella P; Bianchi E; Nardi MC; Steinkühler C; Cortese R; Matassa V; De Francesco R; Pessi A; Bazzo R
    J Mol Biol; 1999 Jun; 289(2):385-96. PubMed ID: 10366512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
    Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.
    Zhang R; Durkin JP; Windsor WT
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1005-8. PubMed ID: 11909704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-peptidic small-molecule inhibitors of the single-chain hepatitis C virus NS3 protease/NS4A cofactor complex discovered by structure-based NMR screening.
    Wyss DF; Arasappan A; Senior MM; Wang YS; Beyer BM; Njoroge FG; McCoy MA
    J Med Chem; 2004 May; 47(10):2486-98. PubMed ID: 15115392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
    J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase.
    De Francesco R; Pessi A; Steinkühler C
    Antivir Ther; 1998; 3(Suppl 3):99-109. PubMed ID: 10726060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, antiviral activity, and conformational studies of a P3 aza-peptide analog of a potent macrocyclic tripeptide HCV protease inhibitor.
    Randolph JT; Zhang X; Huang PP; Klein LL; Kurtz KA; Konstantinidis AK; He W; Kati WM; Kempf DJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2745-50. PubMed ID: 18375121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.
    Tong X; Guo Z; Wright-Minogue J; Xia E; Prongay A; Madison V; Qiu P; Venkatraman S; Velazquez F; Njoroge FG; Malcolm BA
    Biochemistry; 2006 Feb; 45(5):1353-61. PubMed ID: 16445277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases.
    Verhelst SH; Witte MD; Arastu-Kapur S; Fonovic M; Bogyo M
    Chembiochem; 2006 Jun; 7(6):943-50. PubMed ID: 16607671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites.
    Chanprapaph S; Saparpakorn P; Sangma C; Niyomrattanakit P; Hannongbua S; Angsuthanasombat C; Katzenmeier G
    Biochem Biophys Res Commun; 2005 May; 330(4):1237-46. PubMed ID: 15823576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-based inhibitors of the hepatitis C virus NS3 protease: structure-activity relationship at the C-terminal position.
    Rancourt J; Cameron DR; Gorys V; Lamarre D; Poirier M; Thibeault D; Llinàs-Brunet M
    J Med Chem; 2004 May; 47(10):2511-22. PubMed ID: 15115394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Jan; 49(2):567-74. PubMed ID: 16420042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease.
    Malancona S; Colarusso S; Ontoria JM; Marchetti A; Poma M; Stansfield I; Laufer R; Di Marco A; Taliani M; Verdirame M; Gonzalez-Paz O; Matassa VG; Narjes F
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4575-9. PubMed ID: 15357995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB; Pitlik J; Britt SD; Court JJ; Courtney LF; Deininger DD; Farmer LJ; Gates CA; Harbeson SL; Levin RB; Lin C; Lin K; Moon YC; Luong YP; O'Malley ET; Rao BG; Thomson JA; Tung RD; Van Drie JH; Wei Y
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1441-6. PubMed ID: 15006379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.